1. Exciting Bioinformatics Adventures Limsoon Wong Institute for Infocomm Research

2. Plan Treatment optimization of childhood ALL Treatment prognosis of DLBC lymphoma Prediction of translation initiation site Prediction of vaccine target Reliability Assessment of Y2H expts

3. Treatment Optimization of Childhood Leukemia Image credit: FEER

4. Copyright © 2004, 2005 by Jinyan Li and Limsoon Wong Childhood ALL Major subtypes are: T- ALL, E2A-PBX, TEL-AML, MLL genome rearrangements, Hyperdiploid>50, BCR-ABL Diff subtypes respond differently to same Tx Over-intensive Tx –Development of secondary cancers –Reduction of IQ Under-intensiveTx –Relapse The subtypes look similar Conventional diagnosis –Immunophenotyping –Cytogenetics –Molecular diagnostics Unavailable in most ASEAN countries

5. Copyright © 2004, 2005 by Jinyan Li and Limsoon Wong Image credit: Affymetrix Single-Test Platform of Microarray & Machine Learning

6. Copyright © 2004, 2005 by Jinyan Li and Limsoon Wong Multidimensional Scaling Plot Subtype Diagnosis

7. Copyright © 2004, 2005 by Jinyan Li and Limsoon Wong Is there a new subtype? Hierarchical clustering of gene expression profiles reveals a novel subtype of childhood ALL

8. Conclusions Conventional Tx: intermediate intensity to everyone  10% suffers relapse  50% suffers side effects  costs US$150m/yr Our optimized Tx: high intensity to 10% intermediate intensity to 40% low intensity to 50% costs US$100m/yr Copyright © 2004, 2005 by Jinyan Li and Limsoon Wong High cure rate of 80% Less relapse Less side effects Save US$51.6m/yr

9. References E.-J. Yeoh et al., “Classification, subtype discovery, and prediction of outcome in pediatric acute lymphoblastic leukemia by gene expression profiling”, Cancer Cell, 1:133--143, 2002

10. Treatment Prognosis for DLBC Lymphoma Image credit: Rosenwald et al, 2002

11. Diffuse Large B-Cell Lymphoma DLBC lymphoma is the most common type of lymphoma in adults Can be cured by anthracycline-based chemotherapy in 35 to 40 percent of patients  DLBC lymphoma comprises several diseases that differ in responsiveness to chemotherapy Intl Prognostic Index (IPI) –age, “Eastern Cooperative Oncology Group” Performance status, tumor stage, lactate dehydrogenase level, sites of extranodal disease,... Not very good for stratifying DLBC lymphoma patients for therapeutic trials  Use gene-expression profiles to predict outcome of chemotherapy? Copyright © 2005 by Limsoon Wong. Adapted from Huiqing Liu

12. Knowledge Discovery from Gene Expression of “Extreme” Samples “extreme” sample selection: 8 yrs knowledge discovery from gene expression 240 samples 80 samples 26 long- term survivors 47 short- term survivors 7399 genes 84 genes T is long-term if S(T) < 0.3 T is short-term if S(T) > 0.7 Copyright © 2005 by Jinyan Li, Huiqing Liu, and Limsoon Wong

13. p-value of log-rank test: < 0.0001 Risk score thresholds: 0.7, 0.3 Kaplan-Meier Plot for 80 Test Cases Copyright © 2005 by Jinyan Li, Huiqing Liu, and Limsoon Wong

14. (A) IPI low, p-value = 0.0063 (B) IPI intermediate, p-value = 0.0003 Improvement Over IPI Copyright © 2005 by Jinyan Li, Huiqing Liu, and Limsoon Wong

15. (A) W/o sample selection (p =0.38) (B) With sample selection (p=0.009) No clear difference on the overall survival of the 80 samples in the validation group of DLBCL study, if no training sample selection conducted Merit of “Extreme” Samples Copyright © 2005 by Jinyan Li, Huiqing Liu, and Limsoon Wong

16. References H. Liu et al, “Selection of patient samples and genes for outcome prediction”, Proc. CSB2004, pages 382-- 392

17. Protein Translation Initiation Site Recognition

18. 299 HSU27655.1 CAT U27655 Homo sapiens CGTGTGTGCAGCAGCCTGCAGCTGCCCCAAGCCATGGCTGAACACTGACTCCCAGCTGTG 80 CCCAGGGCTTCAAAGACTTCTCAGCTTCGAGCATGGCTTTTGGCTGTCAGGGCAGCTGTA 160 GGAGGCAGATGAGAAGAGGGAGATGGCCTTGGAGGAAGGGAAGGGGCCTGGTGCCGAGGA 240 CCTCTCCTGGCCAGGAGCTTCCTCCAGGACAAGACCTTCCACCCAACAAGGACTCCCCT............................................................ 80................................iEEEEEEEEEEEEEEEEEEEEEEEEEEE 160 EEEEEEEEEEEEEEEEEEEEEEEEEEEEEEEEEEEEEEEEEEEEEEEEEEEEEEEEEEEE 240 EEEEEEEEEEEEEEEEEEEEEEEEEEEEEEEEEEEEEEEEEEEEEEEEEEEEEEEEEEE A Sample cDNA What makes the second ATG the TIS? Copyright © 2005 by Limsoon Wong

19. Approach Training data gathering Signal generation –k-grams, distance, domain know-how,... Signal selection –Entropy,  2, CFS, t-test, domain know-how... Signal integration –SVM, ANN, PCL, CART, C4.5, kNN,... Copyright © 2005 by Limsoon Wong

20. Amino-Acid Features Copyright © 2005 by Jinyan Li, Huiqing Liu, and Limsoon Wong

21. Amino-Acid Features Copyright © 2005 by Jinyan Li, Huiqing Liu, and Limsoon Wong

22. Amino Acid K-grams Discovered (by entropy) Copyright © 2005 by Jinyan Li, Huiqing Liu, and Limsoon Wong

23. Validation Results (on Hatzigeorgiou’s) Using top 100 features selected by entropy and trained on Pedersen & Nielsen’s dataset Copyright © 2005 by Limsoon Wong. Adapted from Huiqing Liu

24. ATGpr Our method Validation Results (on Chr X and Chr 21) Using top 100 features selected by entropy and trained on Pedersen & Nielsen’s Copyright © 2005 by Limsoon Wong. Adapted from Huiqing Liu

25. References L. Wong et al., “Using feature generation and feature selection for accurate prediction of translation initiation sites”, GIW 13:192--200, 2002

26. Image credit: Asif Khan Vaccine Target Prediction

27. T-Cell Epitope Prediction Why? –Only 1%-5% of peptides from a protein bind to any one HLA molecule –Traditional approaches are slow, & inapplicable to large-scale screening  Computer Modeling –Enable systematic screening for HLA binders –Minimize number of expts –Reduce cost 10x Challenges: –There are ~2000 variants of HLA classified in ~20 supertypes –Relatively small number of expt data on peptides that bind HLA molecules –for majority of HLA molecules expt data do not exist H1 H4H3H2 P1 P2 P3 P4 Promiscuous peptides One supertype Copyright © 2005 by Limsoon Wong. Adapted from Asif Khan.

28. Multipred Approach Copyright © 2005 by Asif Khan, Guanglan Zhang, Vladimir Brusic

29. FP FN DR supertype Cut-off Threshold HCV IB protein sequence Copyright © 2005 by Asif Khan, Guanglan Zhang, Vladimir Brusic Expt Validation

30. Accuracy of Multipred Copyright © 2005 by Asif Khan, Guanglan Zhang, Vladimir Brusic

31. Conclusions Computer models are necessary to aid in identification of vaccine targets Prediction models built are both sensitive and specific MULTIPRED can identify promiscuous peptides and immunological hot-spots which are useful for vaccine design Hot-spots are ideal for development of epitope- based vaccines

32. References K.N. Srinivasan, et al. “Predictions of Class I T- cell epitopes: Evidence of presence of immunological hot spots inside antigens”, Bioinformatics, 20:i297-i302, 2004.

33. % of TP based on co-localization % of TP based on shared cellular role (I = 1) % of TP based on shared cellular role (I =.95) TP = ~50% Image credit: Sprinzak et al, 2003 Assessing Reliability of Protein-Protein Interaction Expts

34. Large disagreement betw methods Copyright © 2005 by Limsoon Wong. Adapted from Sprinzak et al, 2003 Some Protein Interaction Data Sets Can we find a way to rank candidate interacting pairs according to their reliability?

35. Copyright © 2005 by Limsoon Wong. Adapted from Chen et al, 2004 Some “Reasonable” Speculations A true interacting pair is often connected by at least one alternative path (reason: a biological function is performed by a highly interconnected network of interactions) The shorter the alternative path, the more likely the interaction (reason: evolution of life is through “add-on” interactions of other or newer folds onto existing ones)  Existence of a strong short alternative path connecting an interacting pair indicates that the interaction is “reliable”

36. Interaction Pathway Reliability Copyright © 2005 by Limsoon Wong. Adapted from Chen et al, 2004

37. The number of pairs not in the intersection of Ito & Uetz is not changed much wrt the ipr value of the pairs The number of pairs in the intersection of Ito & Uetz increases wrt the ipr value of the pairs Evaluation wrt Reproducible Interactions “ipr” correlates well to “reproducible” interactions “ipr” seems to work Copyright © 2005 by Limsoon Wong. Adapted from Chen et al, 2004

38. At the ipr threshold that eliminated 80% of pairs, ~85% of the of the remaining pairs have common cellular roles Evaluation wrt Common Cellular Role, etc “ipr” correlates well to common cellular roles, localization, & expression Copyright © 2005 by Limsoon Wong. Adapted from Chen et al, 2004

39. Evaluation wrt “Many-few” Interactions Number of “Many-few” interactions increases when more “reliable” IPR threshold is used to filter interactions Consistent with the Maslov-Sneppen prediction Part of the network of physical interactions reported by Ito et al., PNAS, 2001 Copyright © 2005 by Limsoon Wong. Adapted from Chen et al., 2004

40. Evaluation wrt “Cross-Talkers” A MIPS functional cat: –| 02 | ENERGY –| 02.01 | glycolysis and gluconeogenesis –| 02.01.01 | glycolysis methylglyoxal bypass –| 02.01.03 | regulation of glycolysis & gluconeogenesis First 2 digits is top cat Other digits add more granularity to the cat  Compare non-co- localized high- & low- IPR pairs to find number that fall into same cat. More high-IPR pairs in same cat, then IPR works For top cat –148/257 high-IPR pairs are in same cat –65/260 low-IPR pairs are in same cat For fine-granularity cat –135/257 high-IPR pairs are in same cat. 37/260 low-IPR pairs are in same cat  IPR works  IPR pairs that are not co-localized are real cross-talkers! Copyright © 2005 by Limsoon Wong.

41. Conclusions There are latent local & global “motifs” that indicate the likelihood of protein interactions These motifs can be exploited in computational elimination of false positives from high- throughput Y2H expts Copyright © 2005 by Limsoon Wong.

42. References J. Chen et al, “Mining high-throughput experimental data for reliable protein interaction data using using network”, 16th IEEE International Conference on Tools with Artificial Intelligence (ICTAI 2004), Florida, November 15-17, 2004

43. Acknowledgements Childhood ALL: –Jinyan Li, Huiqing Liu –Allen Yeoh DLBC Lymphoma: –Jinyan Li, Huiqing Liu Translation Initiation: –Fanfan Zeng, Roland Yap –Huiqing Liu T-Cell Epitopes: –Vladimir Brusic, Asif Khan, Guanglan Zhang –Tom August, KN Srinivasan Protein Interaction Reliability: –Jin Chen, Mong Li Lee, Wynne Hsu –See-Kiong Ng –Prasanna Kolatkar, Jer- Ming Chia